Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

Oncology

Prevalence

75.0 / 100K

Incidence

47.0 / 100K/yr

1 drug in development·1 company·1 clinical trial

Drug Pipeline by Phase

Phase 3(1)
DrugCompany
abp 234AMGEN INC (AMGN)

Frequently asked questions

How many drugs are in development for Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)?

BioSniper tracks 1 drug in development for Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) across 1 company.

How many clinical trials target Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)?

There are 1 clinical trial targeting Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) tracked by BioSniper.

What is the prevalence of Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)?

The estimated prevalence of Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) is approximately 75.0 per 100,000 population.

Deep-dive into Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) — Drugs in Development & Clinical Trials | BioSniper